HealthPharma & Biotech
viewTissue Regenix Group PLC

Tissue Regenix boss to return to full-time duties in June

Steve Couldwell has been out of action so far this year while he undergoes medical treatment

Steve Couldwell
Despite Couldwell’s absence, TRX has “continued to develop in line with expectations”

The chief executive of Tissue Regenix Group PLC (LON:TRX) is to return to full-time duties next month.

At the end of last year, the regenerative medicines specialist confirmed Steve Couldwell would be taking a temporary leave of absence to undergo medical treatment.

READ: Tissue Regenix secures additional coverage for DermaPure from US GPO

“The board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment,” said chairman John Samuel, who held the fort whilst Couldwell was away.

“During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establishing future business developments, along with the support of Gareth Jones who undertook the chief operating officer role during this period.”

Samuel added: “The business has continued to develop in line with the board expectations.”

Quick facts: Tissue Regenix Group PLC

Price: 2.75 GBX

Market: AIM
Market Cap: £32.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Full interview: Tissue Regenix to boost production capacity as its sees...

Tissue Regenix Group PLC's (LON:TRX) Gareth Jones tells Proactive London's Andrew Scott they're focused on initiatives to increase capacity and alleviate supply constraints as they continue to see strong demand for its products. Sales rose £500,000 to £6.1mln during the six months ended...

on 11/9/19

2 min read